XML 109 R51.htm IDEA: XBRL DOCUMENT
v3.3.1.900

Collaborative and Other Relationships (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract] |
Co-promotion profit sharing formula |
Until GAZYVA First Non-CLL FDA Approval | 40.0 | %
After GAZYVA First Non-CLL FDA Approval until First GAZYVA Threshold Date | 39.0 | %
After First GAZYVA Threshold Date until Second GAZYVA Threshold Date | 37.5 | %
After Second GAZYVA Threshold Date | 35.0 | %
First Non-CLL GAZYVA FDA Approval means the FDA’s first approval of GAZYVA in an indication other than CLL. First GAZYVA Threshold Date means the earlier of (1) the date of the First Non-CLL GAZYVA FDA approval if U.S. gross sales of GAZYVA for the preceding consecutive 12 month period were at least $150.0 million or (2) the first day of the calendar quarter after the date of the First Non-CLL GAZYVA FDA Approval that U.S. gross sales of GAZYVA within any consecutive 12 month period have reached $150.0 million. Second GAZYVA Threshold Date means the first day of the calendar quarter after U.S. gross sales of GAZYVA within any consecutive 12 month period have reached $500.0 million. The Second GAZYVA Threshold Date can be achieved regardless of whether GAZYVA has been approved in a non-CLL indication.
Pretax profit sharing formula |
Until First GAZYVA Threshold Date | 39.0 | %
After First GAZYVA Threshold Date until Second GAZYVA Threshold Date | 37.5 | %
After Second GAZYVA Threshold Date | 35.0 | %
Revenues from unconsolidated joint business |
| For the Years Ended December 31,
(In millions) | 2015 |  | 2014 |  | 2013
Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA, including the reimbursement of selling and development expenses (1) | $ | 1,269.8 |  |  | $ | 1,117.1 |  |  | $ | 1,087.3 |
Revenue on sales in the rest of world for RITUXAN | 69.4 |  |  | 78.3 |  |  | 38.7 |
Total unconsolidated joint business revenues | $ | 1,339.2 |  |  | $ | 1,195.4 |  |  | $ | 1,126.0 |
Mechanism for reimbursement, under the amended agreement amounts payable |
|  |  |  |  | Rates post Sobi Opt-In(3)
Royalty and Net Revenue Share Rates: | Method |  | Rate prior to 1st commercial sale in the Sobi Territory: |  | Base Rate following 1st commercial sale in the Sobi Territory: |  | Rate during the Reimbursement Period:
Sobi rate to Biogen on net sales in the Sobi Territory | Royalty |  | N/A |  | 10 or 12% |  | Base Rate plus 5%
Biogen rate to Sobi on net sales in the Biogen North America Territory | Royalty |  | 2% |  | 10 or 12% |  | Base Rate less 5%
Biogen rate to Sobi on net sales in the Biogen Direct Territory | Royalty |  | 2% |  | 15 or 17% |  | Base Rate less 5%
Biogen rate to Sobi on net revenue(1) from the Biogen Distributor Territory(2) | Net Revenue Share |  | 10% |  | 50% |  | Base Rate less 15%
(1) | Net revenue represents Biogen’s pre-tax receipts from third-party distributors, less expenses incurred by Biogen in the conduct of commercialization activities supporting the distributor activities.
(2) | The Biogen Distributor Territory represents Biogen territories where sales are derived utilizing a third-party distributor.
(3) | A credit will be issued to Sobi against its reimbursement of the Opt-in Consideration in an amount equal to the difference in the rate paid by Biogen to Sobi on sales in the Biogen territories for certain periods prior to the first commercial sale in the Sobi Territory versus the rate that otherwise would have been payable on such sales.
Summary of activity related to collaboration with AbbVie Inc. |
| For the Years Ended December 31,
(In millions) | 2015 |  | 2014 |  | 2013
Total development expense incurred by the collaboration | $ | 113.8 |  |  | $ | 117.8 |  |  | $ | 133.4 |
Biogen’s share of development expense reflected in our consolidated statements of income | $ | 60.8 |  |  | $ | 67.4 |  |  | $ | 71.0 |
Summary of activity related to collaboration with Eisai |
| For the Years Ended December 31,
(In millions) | 2015 |  | 2014 |  | 2013
Total development expense incurred by the collaboration | $ | 84.1 |  |  | $ | 57.5 |  |  | $ | — |
Biogen’s share of development expense, excluding upfront and milestone payments, reflected in our consolidated statements of income | $ | 40.4 |  |  | $ | 29.1 |  |  | $ | — |

X
- Definition Co-promotion profit sharing formula. + References No definition available. + Details
Name: | biib_CoPromotionProfitSharingFormulaTableTextBlock
Namespace Prefix: | biib_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Pretax Profit Sharing Formula [Table Text Block] + References No definition available. + Details
Name: | biib_PretaxProfitSharingFormulaTableTextBlock
Namespace Prefix: | biib_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Mechanism for reimbursement, under the amended agreement amounts payable. + References No definition available. + Details
Name: | biib_ReimbursementUnderAmendedAgreementAmountsPayableTableTextBlock
Namespace Prefix: | biib_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Revenues from unconsolidated joint business. + References No definition available. + Details
Name: | biib_RevenuesFromUnconsolidatedJointBusinessTableTextBlock
Namespace Prefix: | biib_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Summary Of Activity Related To Collaboration With Company Eight [Table Text Block] [Table Text Block] + References No definition available. + Details
Name: | biib_SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock
Namespace Prefix: | biib_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Summary of activity related to collaboration with company seven. + References No definition available. + Details
Name: | biib_SummaryOfActivityRelatedToCollaborationWithCompanySevenTableTextBlock
Namespace Prefix: | biib_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration